Anxiety Disorders Therapeutic Pipeline Review H1 2015

DALLAS, April 13, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Anxiety Disorders - Pipeline Review, H1 2015" to its store. The report provides an overview of the Anxiety Disorder's therapeutic pipeline.

The report "Anxiety Disorders - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects.

Anxiety is a normal human emotion that everyone experiences at times. Anxiety Disorders affect about 40 million American adults age 18 years and older (about 18%) in a given year, causing them to be filled with fearfulness and uncertainty. The exact cause of anxiety disorders is unknown. Symptoms vary depending on the type of anxiety disorder, but general symptoms include Feelings of panic, fear, and uneasiness, Problems sleeping, Cold or sweaty hands and/or feet, Shortness of breath, Heart palpitations, An inability to be still and calm, Dry mouth, Numbness or tingling in the hands or feet, Nausea, Muscle tension & Dizziness.

Companies discussed in this report include AbbVie Inc., Ache Laboratorios Farmaceuticos S/A, Adamed Sp. z o.o., Addex Therapeutics Ltd, Avineuro Pharmaceuticals, Inc., Azevan Pharmaceuticals, Inc., Beech Tree Labs, Inc., Bionomics Limited, Boehringer Ingelheim GmbH, C4X Discovery Ltd, Catalyst Pharmaceutical Partners, Inc., Concert Pharmaceuticals, Inc., Edgemont Pharmaceuticals, LLC, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GW Pharmaceuticals plc, H. Lundbeck A/S, Heptares Therapeutics Ltd., HolsboerMaschmeyer NeuroChemie GmbH, Humanetics Corporation, Intra-Cellular Therapies, Inc., Johnson & Johnson, Marinus Pharmaceuticals, Inc., Merz Pharmaceuticals GmbH, MI.TO. Technology S.r.L., Nanotherapeutics, Inc., Neuralstem, Inc., Neurocrine Biosciences, Inc., NeuroNascent, Inc., Newron Pharmaceuticals S.p.A., Novartis AG, Nuvo Research Inc., Omeros Corporation, Otsuka Holdings Co., Ltd., Pfizer Inc., Polleo Pharma Limited, Rottapharm SpA, Sellas Inc., SK Biopharmaceuticals Co., Ltd., Suda Ltd, Sumitomo Dainippon Pharma Co., Ltd., Tonix Pharmaceuticals Holding Corp., Trevena, Inc., Vanda Pharmaceuticals Inc. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310125 . (This is a premium report priced at US$2000 for a single user License.)

Drugs profile discussed in this report include 7-Keto, ADN-2013, ADX-71441, ADX-71743, ADX-88178, alprazolam, AVL-5189, AVN-101, AVN-397, AVN-628, AZ-01, BCA-909, bitopertin, BNC-210, brexpiprazole, BTL-ng, CPP-115, CR-5542 Series, CTP-354, dipraglurant IR, Drug for Post-Traumatic Stress Disorders, Drugs to Activate HAT for CNS Disorders, Drugs to Inhibit FAAH for CNS Disorders, Drugs to Inhibit Histone Deacetylase for CNS Disorders, Drugs to Modulate NPSR for Anxiety Disorder, Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders, E-2508, EDG-008, fluvoxamine maleate, ganaxolone, iloperidone, ITI-007, itriglumide, JNJ-31020028, JNJ-42165279, lorazepam ER, LSN-2535717, LY-2607540, mavoglurant, methoxycoronaridine, midazolam hydrochloride, MRZ-8676, nabiximols, NB-51R1, NNI-351, NSI-189, NTC-942, NW-3509, OMS-527, Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders, Peptide to Antagonize PACAP Receptor for CNS and Overactive Bladder, PF-06372865, PT-00114, PT-00121, PT-00211, PT-00411, Ro-646198, Rycal, S-107, SCT-66, Small Molecule to Agonize mGluR2 for Anxiety Disorders, Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders, Small Molecule to Antagonize GPR31 for Anxiety Disorders Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders, Small Molecule to Modulate Glutamate Receptor for Anxiety Disorders, Small Molecule to Target GPR151 for CNS Diseases, Small Molecule to Target GPR83 for CNS and Immunological Disorders, Small Molecules for BED and PTSD, Small Molecules for Depression and Anxiety, Small Molecules for Post-Traumatic Stress Disorder, Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders, Small Molecules to Activate Sigma Receptor for Panic and Schizoaffective Disorders, Small Molecules to Activate Translocator Protein for Anxiety, Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders, Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder, Small Molecules to Agonize Mineralocorticoid Receptor for Depression and Anxiety, Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders, Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders, Small Molecules to Antagonize TLR-4 for CNS Disorders, Small Molecules to Inhibit DAT and SERT for CNS Disorders, Small Molecules to Inhibit mGluR7 For Central Nervous System Disorders, Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy, Small Molecules to Target Oxytocin for Autism and Anxiety Disorders, SRX-246, SRX-251, Synthetic Peptide for Anxiety Disorders, tedatioxetine, TNX-102, TPI-136117, TRV-250, UCM-765, Vaccine for Post-Traumatic Stress Disorder and Depression, VAD-1, VAD-2, verucerfont, vigabatrin, vortioxetine hydrobromide, YKP-3089, ZL-006 and zolpidem tartrate.

Reasons to buy 

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports on Mental Illness Drugs at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/mental-illness-drugs .

About Us:

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:  

Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@rnrmarketresearch.com